Protagonist Therapeutics Inc (PTGX) — Cash Flow Reinvestment Rate

Latest as of March 2025: 0.76x

Protagonist Therapeutics Inc (PTGX) has a Cash Flow Reinvestment Rate of 0.76x as of March 2025, reinvesting $94.95 Million (capex $545.00K plus investments $-94.40 Million) from operating cash flow of $125.36 Million. Check Protagonist Therapeutics Inc cash earnings quality to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

0.76x
(Capex + Investments) / Operating CF

Total Reinvested

$94.95 Million
Capex + Investments

Operating Cash Flow

$125.36 Million
USD

Capital Expenditures

$545.00K
USD

Protagonist Therapeutics Inc Cash Flow Reinvestment Rate (2017–2024)

Historical reinvestment intensity for Protagonist Therapeutics Inc across 2 annual periods. Explore Protagonist Therapeutics Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.

Annual Cash Flow Reinvestment Rate for Protagonist Therapeutics Inc (2017–2024)

Year-by-year capital reinvestment analysis for Protagonist Therapeutics Inc. For live market cap and broader valuation context, see how much is Protagonist Therapeutics Inc worth.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2024 1.63x $300.84 Million $184.15 Million $1.35 Million ▼ -61.6%
2017 4.26x $16.49 Million $3.87 Million $666.00K
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow